文献速递间质性肺疾病

自身抗体与特发性肺纤维化疾病进展相关

Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2023-05-18

特发性肺纤维化(IPF)患者存在B细胞表型改变,且抗周斑蛋白(PPL)自身抗体阳性者无进展生存期显著更差。小鼠肺纤维化模型显示,肺内给予抗PPL抗体可通过直接激活滤泡树突状细胞、进而驱动成纤维细胞增殖,加重肺损伤、炎症及胶原和纤连蛋白表达。

要点

  • IPF患者存在B细胞表型改变,抗PPL自身抗体与更差的无进展生存期相关。
  • 小鼠模型中抗PPL抗体经滤泡树突状细胞激活成纤维细胞,加重纤维化。
  • IPF患者纤维化灶及外周血中该纤维细胞群体增多,提示潜在治疗靶点。

核心结论

  • IPF患者存在B细胞表型改变,抗PPL自身抗体与无进展生存期显著更差相关。
  • 小鼠肺内给予抗PPL抗体可通过激活滤泡树突状细胞驱动成纤维细胞增殖,加重肺纤维化。

研究设计与样本

  • 研究纳入IPF患者,分析B细胞表型及自身抗体与预后的关系。
  • 采用小鼠肺纤维化模型,肺内给予靶向内源性PPL的抗体。
  • 比较IPF患者与年龄匹配对照的外周血纤维细胞群体。

主要发现

  • IPF患者存在B细胞表型改变。
  • 抗PPL自身抗体阳性IPF患者无进展生存期显著更差。
  • 小鼠肺内给予抗PPL抗体增加肺损伤、炎症、胶原及纤连蛋白表达。
  • 抗PPL抗体直接激活滤泡树突状细胞,进而激活并驱动成纤维细胞增殖。
  • 该纤维细胞群体存在于IPF患者纤维化灶,且外周血中较年龄匹配对照增多。

临床怎么用

  • 抗PPL自身抗体可能作为IPF疾病进展的预后标志物。
  • 靶向自身反应性B细胞或滤泡树突状细胞-成纤维细胞轴可能为IPF治疗提供新方向。

局限性

  • 研究未明确自身抗体与疾病进展的因果关系。
  • 小鼠模型结果外推至人类IPF需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several reports have highlighted a potential role of autoreactive B-cells and autoantibodies that correlates with increased disease severity in patients with idiopathic pulmonary fibrosis (IPF). Here we show that patients with IPF have an altered B-cell phenotype and that those subjects who have autoantibodies against the intermediate filament protein periplakin (PPL) have a significantly worse outcome in terms of progression-free survival. Using a mouse model of lung fibrosis, we demonstrate that introducing antibodies targeting the endogenous protein PPL (mimicking naturally occurring autoantibodies seen in patients) directly in the lung increases lung injury, inflammation, collagen and fibronectin expression through direct activation of follicular dendritic cells, which in turn activates and drives proliferation of fibroblasts. This fibrocyte population was also observed in fibrotic foci of patients with IPF and was increased in peripheral blood of IPF patients compared to aged-matched controls. This study reiterates the complex and heterogeneous nature of IPF, identifying new pathways that may prove suitable for therapeutic intervention.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Koether K, Besnard V, Sandig H, et al. Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis. Eur Respir J. 2023. PMID: 37080573. doi:10.1183/13993003.02381-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。